India Hypoprothrombinemia Treatment Market Size & Outlook, 2026-2034


India Hypoprothrombinemia Treatment Market Insights

  • Reed Intelligence analysis indicates that the India Hypoprothrombinemia Treatment Market size, valued at USD 11.62 Billion in 2025, is expected to expand to USD 24.35 Billion by 2034.
  • The India market is forecasted to expand at a CAGR of 8.73% spanning 2026–2034.
  • Plasma-Derived Products held the leading position among Treatment Type segments in 2025, based on market size.
  • Others is projected to post the fastest growth rate, sustaining its position as the most attractive Treatment Type segment during the forecast horizon.

Other Key Findings


  • In 2025, India accounted for 3.63% of the global Hypoprothrombinemia Treatment Market size.
  • By 2034, United States is expected to lead the global Hypoprothrombinemia Treatment Market in terms of market size.
  • Within Asia Pacific, China is projected to dominate the regional Hypoprothrombinemia Treatment Market size by 2034.
  • Australia is identified as the fastest-growing market in Asia Pacific, anticipated to reach USD 6.31 Billion by 2034.

Report Summary

Report Scope Details
Base Year for Study 2025
Study Period 2022-2034
Historical Period 2022-2024
Forecast Period 2026-2034
Market Size In 2025 USD 11.62 Billion
Market Size In 2034 USD 24.35 Billion
Largest segment Plasma-Derived Products
Units Revenue in USD Billion
CAGR 8.73% (2026-2034)
Segmnetation Covered
Treatment Type
  1. Plasma-Derived Products
  2. Recombinant Therapies
  3. Others
Application
  1. Congenital Hypoprothrombinemia
  2. Acquired Hypoprothrombinemia
End-Use
  1. Hospitals
  2. Specialty Clinics
  3. Home Care Settings
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Related Reports